This article presents the structure of tirzepatide, its mechanism of action, an overview of
clinical trial results, and its safety assessment. Clinical trial results have shown a very …

The incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are responsible for up to 65% of postprandial insulin …

Aim To assess the efficacy and tolerability of tirzepatide treatment using three different dose‐
escalation regimens in patients with type 2 diabetes. Materials and Methods In this double …

The incretin hormone gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-
1) were identified back to 1960's and 1980's, respectively (Yu and Jin, 2010; Baggio and …

Introduction and aim of study: Obesity is a chronic disease associated with numerous health
complications, and the number of patients is steadily increasing. Pharmacological methods …

Purpose To provide an overview of the safety and efficacy, pharmacology, dosing, place in
therapy, and clinical trials for tirzepatide, a novel glucagon-like peptide 1 (GLP-1) and …

There is currently a need for new effective treatments for type 2 diabetes mellitus that
provide adequate glycemic control, resolve associated metabolic abnormalities, and let to …

Type 2 diabetes mellitus (T2DM) is a chronic progressive metabolic disease that has
become a growing health problem worldwide, and the dangers of hyperglycemia and its …

O péptido 1 tipo glucagon (GLP-1) e polipéptido insulinotrópico dependente de glucose
(GIP) são hormônios liberados no cenário de uma refeição, após a ingestão e absorção de …

Tirzepatide is a unimolecular dual agonist of both glucose-dependent insulinotropic
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, which is developed as …